ADIL - Adial Pharmaceuticals Inc

https://www.adial.com

Momentum: Bearish

Recent News

All You Need to Know About Adial Pharmaceuticals ( ADIL ) Rating Upgrade to Buy

Zacks Commentary • 1 week, 6 days ago • score: 0.34

Adial Pharmaceuticals (ADIL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Bullish

Adial Pharmaceuticals ( ADIL ) Upgraded to Strong Buy: Here's Why

Zacks Commentary • 2 months ago • score: 0.37

Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapies for the treatment or prevention of addictions and related disorders. The company is headquartered in Charlottesville, Virginia.

52W High

$1.30

52W Low

$0.22

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.08

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-0.49

EV/Revenue (<3 favorable)

N/A

P/S (TTM) (<3 favorable)

N/A

P/B (<3 favorable)

1.37

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

2.47%

Institutions (25–75% balanced)

2.62%

Shares Outstanding

21,828,200

Float

21,719,700

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-0.71

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-1.71%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-0.0196

-0.0200

Trend

Rising

Signal Cross

No cross

As of

Sep. 12, 2025